Market Place
Sourcing Support
Agios Completes Enrollment of Phase 3 RISE UP Study
23 Oct 2024 //
GLOBENEWSWIRE
Agios To Receive $1.1B In Milestone Payments For Vorasidenib Approval
06 Aug 2024 //
GLOBENEWSWIRE
Agios Announces Phase 3 ACTIVATE-KidsT Study Results
01 Aug 2024 //
GLOBENEWSWIRE
Agios Presents Phase 3 Mitapivat Results In Thalassemia At EHA
15 Jun 2024 //
GLOBENEWSWIRE
Agios` Mitapivat Met Endpoints In Transfusion-Dependent Thalassemias
03 Jun 2024 //
GLOBENEWSWIRE
Agios Pharmaceuticals` blood disorder drug succeeds in late-stage study
03 Jun 2024 //
REUTERS
Agios To Present Rare Blood Disorder Data At EHA 2024
14 May 2024 //
GLOBENEWSWIRE
Agios Reports Business Highlights and First Quarter 2024 Financial Results
02 May 2024 //
GLOBENEWSWIRE
Looking to expand Pyrukynd label, Agios treks toward PIII in sickle cell disease
26 Jun 2023 //
ENDPTS
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Agios Presents PYRUKYND Data Demonstrating Sustained Clinical Benefit in Adults
11 Dec 2022 //
GLOBENEWSWIRE
Agios Presents Updated PYRUKYND® Data Highlighting Long-term Safety Profile
10 Dec 2022 //
GLOBENEWSWIRE
Agios` Pyrukynd Receives Approval in Europe
05 Dec 2022 //
EMA
PYRUKYND® (mitapivat) Approved in the EU for the Treatment of Pyruvate Kinase
10 Nov 2022 //
GLOBENEWSWIRE
Agios Appoints Cecilia Jones as Chief Financial Officer
19 Sep 2022 //
PRESS RELEASE
Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat)
16 Sep 2022 //
GLOBENEWSWIRE
Agios Announces Publication of Phase 3 ACTIVATE-T Data
18 Aug 2022 //
GLOBENEWSWIRE
Agios Announces Publication of Ph2 Data in The Lancet Safety of PYRUKYND®
11 Aug 2022 //
GLOBENEWSWIRE
CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND
13 Jun 2022 //
GLOBENEWSWIRE
Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND
10 Jun 2022 //
GLOBENEWSWIRE
Agios Announces Publication of Phase 3 ACTIVATE Study of PYRUKYND
14 Apr 2022 //
GLOBENEWSWIRE
Agios wins FDA approval for drug to treat rare form of anemia
18 Feb 2022 //
STATNEWS
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile
13 Dec 2021 //
GLOBENEWSWIRE
Agios Submits New Drug Application to FDA for Mitapivat
21 Jun 2021 //
GLOBENEWSWIRE
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat
12 Nov 2020 //
GLOBENEWSWIRE
Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin
11 Jun 2020 //
PRESS RELEASE
US FDA grants orphan drug status to Agios’ PKR activator mitapivat
10 Jun 2020 //
PHARMABIZ
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat
08 Jun 2020 //
GLOBENEWSWIRE
